We are live on ! Find out more
PRQR icon

ProQR Therapeutics
PRQR

18 hedge funds and large institutions have $46.8M invested in ProQR Therapeutics in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

4% more capital invested

Capital invested by funds: $45M → $46.8M (+$1.77M)

0.03% less ownership

Funds ownership: 38.59% → 38.56% (-0.03%)

10% less funds holding

Funds holding: 20 → 18 (-2)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
18
Holders Change
-2
Holders Change %
-10%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$1.94M
2
AG
Artal Group
Luxembourg
+$497K
3
RG
Redmile Group
California
+$214K
4
Morgan Stanley
Morgan Stanley
New York
+$66.2K
5
Wells Fargo
Wells Fargo
California
+$14.9K

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$559K
2
Millennium Management
Millennium Management
New York
-$147K
3
HP
Hikari Power
Japan
-$121K
4
VKH
Virtu KCG Holdings
New York
-$52K
5
CCM
Cribstone Capital Management
Maine
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jennison Associates
1
Jennison Associates
New York
$12.9M -$559K -112,439 -4%
O
2
OrbiMed
New York
$12M – – –
RG
3
Redmile Group
California
$8.3M +$214K +43,050 +3%
ClearBridge Investments
4
ClearBridge Investments
New York
$2.6M +$4K +804 +0.2%
AG
5
Artal Group
Luxembourg
$2.6M +$497K +100,000 +25%
Janus Henderson Group
6
Janus Henderson Group
United Kingdom
$2.03M +$1.94M +390,009 New
SFM
7
Sphera Funds Management
Israel
$1.72M – – –
Franklin Resources
8
Franklin Resources
California
$1.61M – – –
Fidelity Investments
9
Fidelity Investments
Massachusetts
$1.24M – – –
AGA
10
Altrinsic Global Advisors
Connecticut
$995K – – –
Principal Financial Group
11
Principal Financial Group
Iowa
$398K – – –
Morgan Stanley
12
Morgan Stanley
New York
$322K +$66.2K +13,319 +27%
Wells Fargo
13
Wells Fargo
California
$72K +$14.9K +3,000 +28%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$67K +$7K +1,409 +12%
Creative Planning
15
Creative Planning
Kansas
$10K – – –
UBS Group
16
UBS Group
Switzerland
$9K +$8.78K +1,766 New
Royal Bank of Canada
17
Royal Bank of Canada
Ontario, Canada
$3K – – –
PCM
18
Prelude Capital Management
New York
$2K +$1.49K +300 New
Millennium Management
19
Millennium Management
New York
– -$147K -29,444 Closed
HP
20
Hikari Power
Japan
– -$121K -24,144 Closed
VKH
21
Virtu KCG Holdings
New York
– -$52K -10,367 Closed
CCM
22
Cribstone Capital Management
Maine
– -$1K -286 Closed

PRQR Hedge Fund Activity: Q2 2017 in Review

18 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q2 2017, worth a combined $46.8M — up 3.9% from $45M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of PRQR and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 6 added.

The largest buyer was Janus Henderson Group, opening a new position worth an estimated $1.94M. The largest seller was Jennison Associates, cutting an estimated $559K.

  • 18 institutional investors held ProQR Therapeutics (PRQR) as of Q2 2017, down from 20 in Q1 2017.
  • Funds reported $46.8M of ProQR Therapeutics stock for Q2 2017, up 3.9% quarter-over-quarter.
  • 3 funds opened new ProQR Therapeutics positions in Q2 2017 and 4 closed out, a net change of -1 holder.
  • The largest ProQR Therapeutics buyer in Q2 2017 was Janus Henderson Group, an estimated $1.94M added.
  • The largest ProQR Therapeutics seller in Q2 2017 was Jennison Associates, an estimated $559K sold.

Based on aggregated 13F filings for Q2 2017.